Application of Autologous Tumor Vaccine as an Adjuvant Immunotherapy in the Treatment of Metastatic Renal Cell Carcinoma / 대한비뇨기과학회지
Korean Journal of Urology
; : 1106-1109, 2005.
Article
en Ko
| WPRIM
| ID: wpr-111365
Biblioteca responsable:
WPRO
ABSTRACT
About 50% of renal cell carcinoma patients initially present with a regional or distant metastatic disease. Attempts to treat metastatic renal cell carcinomas have been directed at cytokine-based immunotherapy. Response rates of interleukin-2-based immunotherapy of 5 to 29% have been reported in this disease. Immunization as a mechanism to recruit host antitumor responses is increasingly being described as a potentially effective and less toxic approach for the treatment of metastatic and high-risk primary cancers. An autologous renal cell cancer vaccine has been applied at our institution for the prevention of recurrence or metastasis in locally advanced cases for more than one year. Herein, two metastatic renal cell carcinoma cases, which failed to show a response to initial immunotherapy or chemoradiotherapy, which were successfully treated with IL-2 (Aldesleukin) and interferon-alpha as autologous cancer vaccine adjuvants is reported.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Recurrencia
/
Vacunas
/
Carcinoma de Células Renales
/
Inmunización
/
Interleucina-2
/
Interferón-alfa
/
Quimioradioterapia
/
Inmunoterapia
/
Metástasis de la Neoplasia
Límite:
Humans
Idioma:
Ko
Revista:
Korean Journal of Urology
Año:
2005
Tipo del documento:
Article